Trispecific antibodies: is more always better? Advances and boundaries
Precision Clinical Medicine · 11.04.2026 · 9 (2)
DOI: 10.1093/pcmedi/pbag015 ↗Kurz gefasst
Editorial in der Zeitschrift Precision Clinical Medicine, online erschienen am 06.05.2026. Verfasst von Xun Liao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Tianfu Jincheng Laboratory, Chengdu 610212, China. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Tianfu Jincheng Laboratory.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Tianfu Jincheng Laboratory, Chengdu 610212, China.
- Hematologic Malignancies Research Institute, City of Hope National Medical Center, Los Angeles, CA 91010, United States.
- Laboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
ORCID-Profile: Yong Peng
Förderung
- National Natural Science Foundation of China
- Tianfu Jincheng Laboratory
Zitieren
APA
Liao, X., Hou, W., Zhou, J., Feng, L., Ma, R., & Peng, Y. (2026). Trispecific antibodies: is more always better? Advances and boundaries. Precision Clinical Medicine, 9(2). https://doi.org/10.1093/pcmedi/pbag015
Vancouver
Liao X, Hou W, Zhou J, Feng L, Ma R, Peng Y. Trispecific antibodies: is more always better? Advances and boundaries. Precision Clinical Medicine. 2026;9(2). doi:10.1093/pcmedi/pbag015
BibTeX
@article{Liao2026,
author = {Liao, Xun and Hou, Wenjie and Zhou, Junxiu and Feng, Liang and Ma, Rui and Peng, Yong},
title = {Trispecific antibodies: is more always better? Advances and boundaries},
journal = {Precision Clinical Medicine},
year = {2026},
volume = {9},
number = {2},
doi = {10.1093/pcmedi/pbag015}
}
EUVIMED